Cangene's NDA for human growth hormone accepted for review by Food and Drug Administration

By Lisa Kerner

Charlotte, N.C., July 17 - Cangene Corp. said its New Drug Application for the recombinant human growth hormone product Accretropin has been accepted for review by the Food and Drug Administration for the treatment of short stature in children with growth hormone deficiency and girls with the X-chromosome-linked genetic disorder Turner Syndrome.

"This is our first recombinant biopharmaceutical to be filed with the FDA and adds to the future potential and diversity of our already strong pipeline, which includes a number of biodefense and infectious disease targeted drugs along with the recombinant products," president and chief executive officer John Langstaff said in a company news release.

Cangene is a biotechnology research and development company located in Winnipeg, Manitoba.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.